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Research Article 
Abstract 
Dengue and Chikungunya are two major arboviral infections transmitted worldwide by the mosquitoes, Aedes aegypti and Ae. 
albopictus. India suffers enormously with both Dengue and Chikungunya as they pose a great public health challenge. The pre-
sent study aims to evaluate the prevalence of Dengue Virus (DENV), Chikungunya Virus (CHIKV) and DENV/CHIKV co-
infection (by Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)/Enzyme Linked Immunosorbent Assay (ELISA), 
their clinical features, DENV serotypes and CHIKV specific Immunoglobulin G (IgG) within a 7 years gap in the Delhi population. 
The study sample included clinically suspected febrile patients (≤7 days) sera collected during 2017-2018 (n=87) and during 
2008-2010 (n=623) from Delhi. Captured ELISA was performed for CHIKV IgG screening and nested PCR was done for DENV 
serotyping. The percentage prevalence for DENV was significantly higher than CHIKV with 41.38% (n=87) and 16.1% (n=87), 
respectively; interestingly, DENV/CHIKV co-infection was detected in 10.34% (n=9/87) cases during 2017-2018. Similarly, a 
high DENV prevalence was observed during 2008-2010 with the prevalence rate of 38.3% (69/180),  34.65% (35/101) and 
47.07% (161/342), respectively. DENV 1 and DENV 3 were dominant serotype during 2008-2010 and 2017-2018 respectively. 
We have noticed a high prevalence (36.67%, 22/60) of the CHIKV IgG antibody in the 2017-2018 samples. Joint pain was more 
preferential to CHIKV mono-infection and DENV/CHIKV co-infection compared to DENV mono-infection. The present study 
highlights the need for active surveillance simultaneously for both DENV and CHIKV and to evaluate the role of CHIKV/DENV 
co-infections in disease severity in the endemic regions.  
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INTRODUCTION 
Acute febrile illness is an undifferentiated fever condi-
tion which can be observed in adults as well as children 
of various age groups. The possible cause may be ei-
ther of dengue, malaria, leptospirosis, chikungunya, 
japanese encephalitis, typhoid, rickettsia, influenza A 
(Hammon et al., 1960; Gubler, 1998; Requena-Castro 
et al., 2017; Singh et al., 2018). The pathogens causing 
febrile illnesses like dengue fever, chikungunya fever, 
malaria., are transmitted by arthropod vectors, precisely 
the mosquitoes. Diseases caused by arboviruses are 
responsible for the burden on the health-care system 
worldwide (Singh et al., 2018). Both Dengue Virus 
(DENV) (Flavivirus, Flaviviridae) and Chikungunya  
Virus (CHIKV) (Alphavirus, Alphaviridae)  account for 
major public health concerns due to significant morbidi-
ty and mortality (especially in the case of dengue). 
There are 4 serotypes for the dengue virus (DENV 1-4) 
(Gubler, 1998). Infection with a heterologous serotype 
may cause more complications like Dengue Haemor-
rhagic Fever (DHF) which necessitates the identification 
of DENV serotypes (Hammon et al., 1960; Requena-
Castro et al., 2017) so that appropriate epidemiological 
data can be maintained and the patient could be provid-
ed with necessary health care. These viral infections 
show similar clinical symptoms like high-grade fever, 
joint pain, rashes, headache, and vomiting (Taraphdar 
et al., 2012). However, recent have studies reported 
that multiple joint pain is the characteristic feature of 
chikungunya virus infection and may persist for several 
months in the knee, wrist, finger, and ankles (Simon et 
al., 2007; Burt et al., 2012). Delhi is an endemic region 
for DENV infection, therefore, its cases are regularly 
reported every year. Its recent outbreaks have been 
reported in 2010, 2013, and 2015 (Kumari et al., 2011; 
Afreen et al., 2014a; Savargaonkar et al., 2018). A total 
of 9271 and 7136 dengue cases were reported in 2017 
and 2018, respectively, from Delhi {National Vector 
Borne Disease Control Programme (NVBDCP)} while 
940 and 407 cases of chikungunya fever were reported 
during 2017 and 2018 from Delhi (NVBDCP). 
Chikungunya is a re-emerging arboviral disease that 
occurs intermittently in the region where dengue is en-
demic. Due to a lack of appropriate diagnostic kits for 
CHIKV, there is no robust surveillance system for 
CHIKV screening so the true disease burden always 
remains unclear. Alternatively, it is a better idea to 
screen CHIKV specific IgG in acute samples in addition 
to CHIKV specific IgM. In dengue-endemic areas, the 
chances of chikungunya infection may be high as both 
the viruses are transmitted by common mosquito vec-
tors Aedes aegypti and Aedes albopictus (Furuya-
Kanamori et al., 2016). Human DENV/CHIKV co-
infection may occur through the bite of a co-infected 
mosquito or due to super-infection (Rosso et al., 2016; 
Zaidi et al., 2018). Some studies have reported the 
prevalence of DENV/CHIKV co-infection from Delhi 
(9.8% and 10%) and West Bengal (22.4%) (Taraphdar 
et al., 2012; Singh et al., 2012; Afreen et al., 2014a). 
The same clinical manifestation of DENV and CHIKV 
patients  makes the diagnosis of DENV/CHIKV co-
infected patients very difficult clinically and proper man-
agement of patients. Therefore, laboratory-based de-
tection of co-infection is very necessary. Due to com-
mon vectors, the same clinical symptoms and overlap-
ping geographical distribution of both infections, the 
clinical practitioners invariably need to know the preva-
lence rate of DENV/CHIKV co-infection and to differen-
tiate between dengue and chikungunya infection in the 
initial stage with the help of appropriate early detection 
kits. This helps in the strategic management of disease 
severity through optimal therapeutic agents (Subudhi et 
al., 2018). 
The main objectives of the present study are (i) to de-
termine the prevalence of CHIKV, DENV, and DENV/
CHIKV co-infection in the years 2017-2018 from Delhi 
and comparison of DENV prevalence with the preva-
lence from Delhi during 2008-2010 (ii) to evaluate clini-
cal features of DENV, CHIKV, and co-infected (DENV 
& CHIKV) patients, (iii) determination of DENV serotyp-
ing and (iv) to access the immunological status of 
CHIKV patients. 
MATERIALS AND METHODS 
Ethical clearance 
This study was approved by the Institutional Ethical 
Committee of Jamia Hamdard, New Delhi, and AIIMS, 
New Delhi. Blood samples were collected from all pa-
tients by taking written informed  consent. 
Patients and clinical samples 
Blood samples were collected from patients having 
fever ≤7 days duration, attending the Out/In-patient 
department of Hakeem Abdul Hameed (HAH) Cen-
tenary Hospital, Jamia Hamdard, New Delhi from Octo-
ber 2017 to November 2018. This study was approved 
by the Institutional Ethical Committee of Jamia 
Hamdard, New Delhi, and AIIMS, New Delhi. The pa-
tient’s, details including clinical symptoms were record-
ed after taking consent from the patients or parents/
guardians of children. A total of 87 patients were en-
rolled which included 42 from the year 2017 and 45 
from the year 2018. At the initial stage of recruitment, 
samples were screened for the dengue day 1 test (J 
Mitra and Co.), and for chikungunya advantage IgM 
card (J Mitra and Co.) was used. Additionally, samples 
were subjected to core stringent laboratory diagnoses 
as outlined in the next section. We had also collected 
samples from dengue suspected patients from June 
2008 to December 2010, from AIIMS, New-Delhi. In  
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2010 Delhi witnessed a dengue fever outbreak so 
these samples have great importance as far as epide-
miology is concerned. A total of 623 acute-phase se-
rum samples were collected having D.O.F ≤7. The total 
number of collected cases were 180 in 2008, 101 in 
2009, and 342 in 2010. The study included these sam-
ples for comparison of DENV prevalence and its sero-
typing trend between the years 2017-2018 and 2008-
2010. This is important for a better understanding of 
DENV epidemiology. 
DENV and CHIKV diagnosis 
All the blood samples collected during 2017-2018 were 
screened for CHIKV infection by using CHIKV RT-PCR 
and/or an anti-CHIKV IgM ELISA kit (Abcam) (Ray et 
al., 2012). DENV infection was detected by using the 
Dengue NS1 Ag ELISA kit by following the manufactur-
er's protocol (Euroimmun) (Palomares-Reyes et al., 
2019) (Fig 1). To assess the CHIKV prior infection, 
CHIKV specific IgG antibodies were screened by using 
an anti-CHIKV IgG ELISA kit (Abcam) (Nayak et al., 
2020) (Fig 1). 
All the blood samples collected during 2008-2010 were 
tested for dengue virus by IgM ELISA and/or NS1 anti-
gen ELISA (Fig 1). SD BIOLINE Dengue Duo Combo 
device (Standard Diagnostic Inc., Korea) for IgM ELISA 
and anti-dengue NS1 based ELISA kit (J. Mitra & Co. 
Pvt. Ltd. India) for NS1 antigen detection were used for 
DENV screening. 
 RNA extraction and RT-PCR 
RNA isolation and cDNA synthesis were done by fol-
lowing previously reported protocol (Afreen et al., 
2014a). For detection of CHIKV by PCR, published 
primers were used and the 294 bp E1 gene was ampli-
fied and analyzed as described previously (Hasebe et 
al., 2002). 
Determination of DENV serotype 
DENV serotyping was performed for all the NS1 posi-
tive samples (n=36) from the 2017-2018 study period 
of which 16 samples turned out negative by RT-PCR; 
therefore, these 16 samples were subjected to virus 
isolation on the Vero cell line followed by RT-PCR 
(Medina et al., 2012). Briefly, 50μl sera were diluted to 
make 200μl volume in plain DMEM media then inocu-
lated in the fresh monolayer of the Vero cell line. Sam-
ples were cultured for 3-5 days until the cytopathic ef-
fect is observed. After this, the supernatant was collect-
ed and carried for RT-PCR cDNA synthesized from 
NS1 Ag positive samples were subjected to PCR. First-
round PCR was followed by nested PCR. The sizes of 
the PCR products were 119 bp for DENV 2, 290 bp for 
DENV 3, and 392 bp for DENV 4 (Lanciotti et al., 1992; 
Fig. 1. Schematic representation of patients’ plasma samples analyzed for DENV and CHIKV. 
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Chahar et al., 2009). Agarose gel electrophoresis (2%) 
was used for analyzing the PCR products (Fig 2). Simi-
larly, a total of 69 samples were selected from 2008-
2010 collected samples for DENV serotyping. 
Statistical analysis 
Graph Pad Prism software, version 5.2 was used for 
data analysis. Fischer’s exact test was employed to 
compare the clinical symptoms in CHIKV, DENV, and 
DENV/CHIKV co-infection. For analysis purposes, we 
considered the value of  P<0.05 as significant (Azeredo 
et al., 2018). 
RESULTS 
Prevalence of CHIKV & DENV in febrile patients 
A total of 87 sera were tested for chikungunya by both 
genomic (RT-PCR) and serological based (IgM) test of 
which 16.1% were found positive for CHIKV infection 
only by IgM; none was detected CHIKV RNA positive 
(Table 1). The median age of CHIKV infected patients 
was 26 years. Males (57.14%, n=8/14) were more in-
fected with CHIKV than females (42.85%, 6/14), alt-
hough not found statistically significant. In 2017, CHIKV 
positivity was 9.5% (4/42), whereas in 2018, it was 
22.22% (10/45). Dengue infection was found in 41.38% 
(36/87) cases by NS1 Ag ELISA (Table 1). We did not 
find any NS1 Ag ELISA positive samples positive by RT
-PCR, but we could able to determine DENV serotyping 
by nested PCR. The median age of DENV infected pa-
tients was 24.5 years and males (55.88%, n=19/34) 
were more affected than females (44.12%, n=15/34). 
DENV infections were 33.33% (14/42) in the year 2017 
and 48.89% (22/45) in the year 2018 while the preva-
lence of DENV infection was 38.3% (69/180) in 2008, 
34.65% (35/101) in 2009 and 47.07% (161/342) in 2010 
(Fig 3). 
Prevalence of anti-CHIKV antibodies in patients 
during 2017-2018 
Out of total screened samples (n=87), CHIKV specific 
IgM antibodies were detected in 16.1% (14/87) samples 
and CHIKV specific IgG antibodies were detected in 
36.67% (22/60) samples. This IgG prevalence data 
gives a rough estimation of previous exposure of pa-
tients under study. Only 16.36% (9/55) samples were 
found positive for both IgM and IgG whereas 9.1% 
(5/55) samples were detected IgM positive only. The 
Virus 
  
No. of subjects 
tested 
No (%) of positivity 
ELISA RT-PCR Total positivity 
  CHIKV IgM /DENV NS1 Ag CHIKV 
CHIKV 87 14 (16.1) 0 14 (16.1) 
DENV 87 36* (41.38) - 36 (41.38) 
DENV + CHIKV 
co-infection 
87 - - 9 (10.34) 
Table 1. RT-PCR and ELISA based detection of DENV, CHIKV, and DENV/CHIKV co-infection among 87 clinically  
suspected cases from October 2017 to November 2018 in Delhi. 
Note- Data is no (%) of patients; 
*DENV NS1 positive samples were further taken for serotyping. 










(DENV + CHIKV) 
(C=8) 
P-value 
A vs B A vs C B vs C 
Rash 
  
0 3 (14.29) 2 (25) 1.000 0.515 0.597 
Headache 
  
3 (75) 19 (90.47) 6 (75) 0.422 1.000 0.300 
Joint pain 
  
3 (75) 9 (42.86) 6 (75) 0.322 1.000 0.215 
Joint swelling 
  
1 (25) 0 1 (12.5) 0.160 1.000 0.276 
Abdominal pain 1 (25) 7 (33.33) 
2 (25) 
  
1.000 1.000 1.000 
Diarrhea 
  
0 3 (14.29) 2 (25) 1.000 0.515 0.597 
Cough 
  
1 (25) 9 (42.86) 3 (37.5) 0.627 1.000 1.000 
Vomiting 
  
2 (50) 16 (76.19) 4 (50) 0.549 1.000 0.209 
Rhinitis 0 2 (9.5) 0 1.000 1.000 1.000 
Note. Data are no. (%) of patients; P-value was calculated by using the Fischer exact test.  
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percentage of samples found IgG positive and IgM neg-
ative was 12.73% (7/55) (Fig 4). 
Prevalence of DENV/CHIKV co-infection during 
2017-2018 in Delhi 
We found the  co-circulation of DENV and CHIKV in the 
studied patients and  noticed the co-infection of both 
pathogens in a significant proportion. We have found 
the prevalence of DENV/CHIKV co-infection to 10.34% 
(9/87) (Table 1). Their median age was 31 years and 
females (66.67%, n=6/9) appear to become more prone 
to the infection than males (33.33%, n=3/9). The study 
of the age-wise distribution of DENV, CHIKV, and DEN-
V/CHIKV co-infection showed that the maximum infect-
ed patients were from the age group of 18-35 years 
(Fig 5). 
DENV serotyping 
Out of 36 DENV NS1 Ag positive samples of the year 
2017-2018, we were able to determine serotype for 
only 29 (80.56%, 29/36) samples. The most dominant 
serotype during this study was DENV 3. DENV 3 was 
detected in 27 (75%, 27/36) samples whereas DENV 4 
was detected in 1 (2.78%, 1/36) sample. The infection 
of a patient with more than one serotype was observed 
in 1 (2.78%, 1/36) sample only and the detected sero-
types were DENV 2 and 3. We could not find DENV 1 
during this course of study. DENV 2, 3, and 4 were 
found circulating during 2017 whereas, during 2018 
only DENV 3 was found circulating in studied samples 
in Delhi. Furthermore, all DENV/CHIKV co-infected 
patients were infected with DENV 3 serotype whereas 
DENV mono-infected patients were infected with DENV 
3, DENV 4, and mixed serotype (DENV 2 and 3) (Fig 
6). In 7 DENV NS1 Ag positive samples, infecting sero-
type could not be determined. On the other hand, we 
could determine DENV serotyping of 69 samples only 
collected from AIIMS during 2008-2010 and identified 
DENV 1 in 43.48% (30/69) and DENV 2 in 4.35% 
(3/69) samples (Fig 6). We could not find DENV 3 or 
DENV 4 serotype in any of the samples. 
Evaluation of clinical symptoms of DENV mono-
infected, CHIKV mono-infected, and DENV/CHIKV 
co-infected adults (≥18 years)  
Clinical symptoms were analyzed for CHIKV mono-
infected, DENV mono-infected, and DENV/CHIKV co-
infected (Table 2) adult patients of the year 2017-2018. 
Fig. 2. Agarose gel pics (2%) showing amplified DNA bands of DENV serotypes. (A) Lane 1-6 showed DENV 2,3, and 4 
serotypes, negative control (Lane 7), and M indicates a 50 bp DNA ladder. (B) DENV 3 serotype (lane 2-10) where lane 
1 is a negative control. 
Fig. 3. Graphical representation of the year-wise prevalence 
of DENV infection in Delhi.  
Fig. 4. Graphical representation of CHIKV patients showing 
the serological status of 2017-2018 collected samples. 
 
438 
Sagar, R. et al. / J. Appl. & Nat. Sci. 13(2), 433 - 442 (2021) 
Although joint pain was found in all the adult groups, 
the relative proportion with joint pain was higher in 
CHIKV mono-infection compared to dengue mono-
infection (75% versus 42.86%) but the relative propor-
tion with joint pain was similar in CHIKV/DENV co-
infection compared to CHIKV mono-infection (75% ver-
sus 75%). Joint swelling was found in both CHIKV 
mono-infection and DENV/CHIKV co-infection but was 
absent in DENV mono-infection. In addition to this, the 
relative proportion with joint swelling was double in 
CHIKV mono-infection as compared to CHIKV/DENV 
co-infection (25% versus 12.5%). Vomiting, however, 
appears to be preferential to dengue mono-infection 
(76.19%) compared to either CHIKV mono-infection 
(50%) or DENV/CHIKV co-infection (50%) (Table 2). 
DISCUSSION 
Delhi is a dengue-endemic region and witnessed  many 
dengue fever outbreaks. Therefore its molecular sur-
veillance is necessary every year to make  appropriate 
decisions can be made on existing and future strate-
gies for proper management of dengue disease. In this 
study, we have found a high prevalence of dengue vi-
rus in Delhi during 2008-2010 but in 2010, the preva-
lence was slightly higher than 2008 and 2009, the pos-
sible reason may be the occurrence of dengue out-
break during the year and this finding is consistent with 
the prevalence reported from Delhi (Ahmed and Broor, 
2015). In Delhi, from time to time different dengue posi-
tivity was reported as 49% during 2011 (Afreen et al., 
2014a), 69% during 2011-2014 (Afreen et al., 2015), 
71% during the 2013 outbreak (Afreen et al., 2014b), 
61% during 2015 outbreak (Savargaonkar et al., 2018) 
and 40% during 2016 (Hisamuddin et al., 2018). But in 
this study during 2017 dengue cases becomes slightly 
lower and during 2018 again increased to 49%.  
DENV/CHIKV co-infection is very common in dengue-
endemic regions due to the overlapping epidemiology 
of both diseases. To know the prevalence of DENV/
CHIKV co-infection, it is necessary to know the preva-
lence of CHIKV in dengue-endemic regions. In our 
study, we observed a 16.1% prevalence rate of CHIKV 
which is relatively high as compared to other reports  
(Rezza et al., 2014; Dinkar et al., 2018; Savargaonkar 
et al., 2018; Murhekar et al., 2019). Due to the chang-
ing epidemiology of CHIKV, it is necessary for active 
Fig. 5. Age-wise distribution of DENV, CHIKV and DENV/
CHIKV co-infection. 
Fig. 6. A. Representation of the year-wise prevalence of DENV serotypes. B. DENV serotypes were detected in DENV 
mono-infection and DENV/CHIKV co-infected patients’ samples collected during 2017-2018. 
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molecular surveillance of CHIKV in dengue-endemic 
regions so that the true disease burden can be deter-
mined. To know the rough estimation of previous expo-
sure of patients under study to CHIKV infection and 
also for planning CHIKV vaccine studies, prevalence 
data of IgG antibodies is required. As there is no robust 
surveillance system existing for CHIKV screening so it 
can be an alternative approach to screen CHIKV spe-
cific IgG towards knowing CHIKV disease burden. We 
have found a high prevalence of CHIKV IgG in this 
study which is inconsistent with a study from Pune 
(Patil et al., 2020). To check CHIKV's recent infection, 
we screened IgG positive samples for IgM positivity. 
Only 16.36% of samples were tested positive for the 
presence of IgM antibodies which indicate CHIKV infec-
tion may not have been very recently during the study. 
The antibody response patterns might vary between 
mono-infected and co-infected patients. Hence, it is 
very important to determine the mono-infection and co-
infection status of the patients as the antibodies pat-
terns generated in response to the infection might 
serve as biomarkers for disease progression (Nayak et 
al., 2020). 
The prevalence of DENV/CHIKV co-infection was previ-
ously reported to 8.6% and 10% from Delhi during 2006 
(Chahar et al., 2009) and 2011 (Afreen et al., 2014a) 
respectively. In our study, we have also found a high 
prevalence rate of DENV/CHIKV co-infection. This find-
ing agrees with other reports from Delhi (Hisamuddin et 
al., 2018), Varanasi (Singh et al., 2018), Mumbai 
(Londhey et al., 2016), Pune (Gandhi et al., 2015). The 
age group of 18-35 years was observed most affected 
group among DENV, CHIKV, and DENV/CHIKV co-
infection, and this is supported by a study from Punjab 
and West Bengal (Mukherjee et al., 2017; Kaur et al., 
2018). 
When clinical symptoms were analyzed, we observed 
that joint pain and joint swelling both were more in 
CHIKV mono-infection and DENV/CHIKV co-infection. 
This finding agrees with other reports (Dinkar et al., 
2018; Singh et al., 2018). DENV mono-infected patients 
had more vomiting in comparison to CHIKV  mono-
infected or DENV/CHIKV co-infected patients. This is 
also consistent with other reports (Edwards et al., 2016; 
Dinkar et al., 2018; Singh et al., 2018). Thus, it appears 
that whenever there is a CHIKV component involved, 
regardless of mono or co-infection, there is a higher 
chance of joint pain and joint swelling. By contrast, 
wherever there is a CHIKV component involved regard-
less of mono-infection or co-infection, vomiting was 
relatively lower compared to dengue. These trends, 
although statistically insignificant, holds true even when 
comparing children and adult groups (data not shown). 
This however may be studied more deeply in future to 
corroborate. 
A previous study on DENV/CHIKV co-infection reported 
that co-infection causes more severe clinical disease 
than mono-infection (Chahar et al., 2009; Gandhi et al., 
2015), but our study did not find any clinical symptom 
which was associated with only DENV/CHIKV co-
infection. Therefore, it is reconfirmed that DENV/CHIKV 
co-infection does not exacerbate the clinical severity 
(Caron et al., 2012; Zaidi et al., 2018; Singh et al., 
2018). 
Delhi witnessed many dengue fever episodes every 
year which were attributed to a particular dengue virus 
serotype. During this study, we have identified DENV 3 
as a dominant serotype which is consistent with other 
reports from Delhi during 2016 (Parveen et al., 2019). 
In Delhi during 2006, DENV 2 was a dominant sero-
type. It was replaced by DENV 1 during 2007-2009 
(Chakravarti et al., 2010) and became dominant in the 
2010 outbreak (Ahmed and Broor, 2015). Then DENV 
2 became dominant from 2011-2015 (Afreen et al., 
2014a, Afreen et al., 2014b., Afreen et al., 2015). To 
the best of our knowledge, no dengue fever epidemics 
are attributed to DENV 4 in Delhi. DENV 2 was the pre-
dominant serotype in monotypic DENV patients in West 
Bengal during 2014-2015 (Mukherjee et al., 2017; Sa-
vargaonkar et al., 2018). To know whether any particu-
lar serotype is associated with DENV/CHIKV co-
infection, we determined the serotyping of co-infected 
samples also. We found DENV 3 serotype in all DENV/
CHIKV co-infected patients. In contrary to this, reports 
from Delhi and Laos evidenced the different DENV 
serotypes in co-infected patients (Afreen et al., 2014a; 
Phommanivong et al., 2016). A report from Delhi evi-
denced circulation of DENV 2 followed by DENV 3 as 
the major serotype in DENV/CHIKV co-infected pa-
tients during 2011 (Afreen et al., 2014a). Previously, it 
has been reported that DENV 3 infected patients 
showed hepatomegaly (Kumaria, 2010) and elevated 
levels of liver enzymes, AST, and/or ALT in the DHF 
condition (Rezza et al., 2014). Infection of patients with 
multiple DENV serotypes was reported more likely to 
have clinical severity as compared to patients infected 
with only one serotype (Dhanoa et al., 2016). The 
change in serotyping pattern and clinical severity with 
multiple serotypes necessitates the determination of 
DENV serotyping over the period which is necessary 
for proper preventive measures and clinical manage-
ment of patients and vaccine trials. Although we have 
reported only one case of concurrent infection with mul-
tiple serotypes in Delhi due to hyper-endemicity, the co-
circulation of multiple serotypes in Delhi is very com-
mon (Afreen et al., 2014b). Although reasons remain to 
be fully understood, it is presumed that due to low viral 
titer, we could not determine the serotype of 7 DENV 
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Conclusion  
Our prevalence data highlights the need for active sur-
veillance of DENV/CHIKV co-infection especially in the 
endemic regions for both viruses. Our study also high-
lights that DENV/CHIKV co-infection does not always 
involve  the exacerbation of clinical features. Our study 
provides the prevalence data on CHIKV and DENV and 
dengue virus serotyping which is required for under-
standing the epidemiology of both arboviral diseases 
and will be helpful for vaccine developers and proper 
clinical management of CHIKV and DENV infected pa-
tients. Epidemiological data of any disease plays a sig-
nificant role in making better policies and initiations of 
any vaccine trials by the health workers. Therefore, 
epidemiological surveillance has a key role in proper 
disease management. This study found the prevalence 
of DENV (41.38%), CHIKV (16.1%), and DENV/CHIKV 
coinfection (10.34%). Sometimes, secondary infection 
with DENV heterologous serotypes{(Dengue Haemor-
rhagic Fever (DHF) and Dengue Shock Syndrome 
(DSS)}  may lead to complications and even death of 
the infected patients.  So, tracking the DENV serotype 
is very important for the proper management of DENV 
patients. The Dominance of DENV serotypes (1,2,3) 
varied in different time periods of our study. Clinical 
symptoms  revealed that DENV/CHIKV co-infection did 
not exacerbate the clinical severity  compared to DENV 
and CHIKV mono-infected patients. 
Declarations 
Funding 
This study partially received financial support from the 
Department of Biotechnology, Government of India 
during 2008-2010 but we did not receive any specific 
grant from funding agencies in the public, commercial, 
or not-for-profit sectors during the study period 2017-
2018. 
Compliance with ethical standards 
This study was approved by the Institutional Ethical 
Committee of Jamia Hamdard, New Delhi, and AIIMS, 
New Delhi. The procedure used in this study adheres to 
the tenets of the declaration of Helsinki. Human pa-
tient’s blood samples were collected from all patients 
by taking written informed consent. 
Consent to participate 
Informed written consent was taken from all patients 
who participated in the study. 
Author’s contributions 
RS performed the experiments and analyzed the data 
and wrote the initial manuscript. VJ helped in sample 
collection. AC, MK, and AKP helped in the clinical study 
design. SR and KN reviewed the initial manuscript. 
KKG reviewed the manuscript, helped in data analysis, 
editing and finalizing the manuscript. NK and PR super-
vised the whole study including study design and final 
editing of the manuscript. All authors read and ap-
proved the final manuscript. 
ACKNOWLEDGEMENTS 
RS acknowledges the JRF fellowship from the Universi-
ty Grant Commission, Govt. of India. The authors grate-
fully acknowledge Ms. Shipra Gupta for useful com-
ments on the manuscript. 
Conflict of interest 




1. Afreen, N., Deeba, F., Khan, W. H., Haider, H. S., Kazim, 
S. N., Ishrat, R, Naqvi I. H., Shareef, M. Y., Broor, S., 
Ahmed, A. & Parveen, S. (2014a). Molecular characteriza-
tion of dengue and chikungunya virus strains circulating in 
New Delhi, India. Microbiol Immunol., 58:688–696. https://
doi.org/10.1111/1348-0421.12209 
2. Afreen, N., Deeba, F., Naqvi, I., Shareef, M., Ahmed, A., 
Broor, S., & Parveen, S. (2014b). Molecular investigation 
of 2013 dengue Fever outbreak from delhi, India. PLoS 
Curr 6:. https://doi.org/10.1371/currents.outb reaks.0411 
252a8b82aa933f6540abb54a855f 
3. Afreen, N., Naqvi, I. H., Broor, S., Ahmed, A. & Parveen, 
S. (2015). Phylogenetic and Molecular Clock Analysis of 
Dengue Serotype 1 and 3 from New Delhi, India. PLOS 
ONE, 10:e0141628. https://doi.org/10.1371/journal.po 
ne.0141628 
4. Ahmed, N. & Broor, S. (2015). Dengue Fever Outbreak in 
Delhi, North India: A Clinico-Epidemiological Study. Indian 
journal of community medicine : official publication of Indi-
an Association of Preventive & Social Medicine, 40,135–
138. https://doi.org/10.4103/0970-0218.153884 
5. Azeredo, E. L., Dos Santos, F. B., Barbosa, L. S., Alva 
Souza, T.M., Badolato-Correa, J., Sanchez-Arcila, J.C., 
Nunes, P.C.G., De-Oliveira-Pinto, L.M., De Filippis, A.M., 
Fabbro, M.D., Romanholi, I.H., & Da Cunha, R.V. (2018). 
Clinical and Laboratory Profile of Zika and Dengue Infect-
ed Patients: Lessons Learned From the Co-circulation of 
Dengue, Zika and Chikungunya in Brazil. PLoS Curr., 10. 
https://doi.org/10.1371/
currents.outbreaks.0bf6aeb4d30824de63c4d5d745b217f5 
6. Burt, F. J., Rolph, M. S., Rulli, N. E., Mahalingam, S. & 
Heise, M. T. (2012). Chikungunya: a re-emerging virus. 
Lancet, 379,662–671. https://doi.org/10.1016/S0140-6736
(11)60281-X 
7. Caron, M., Paupy, C., Grard, G., Becquart,P., Mombo, I., 
Nso, B. B. B., Kassa, F. K., Nkoghe, D. & Leroy, E. M. 
(2012). Recent introduction and rapid dissemination of 
Chikungunya virus and Dengue virus serotype 2 associat-
ed with human and mosquito coinfections in Gabon, cen-




Sagar, R. et al. / J. Appl. & Nat. Sci. 13(2), 433 - 442 (2021) 
8. Chahar, H. S., Bharaj, P., Dar, L., Guleria, R., Kabra, S. K. 
& Broor, S. (2009). Co-infections with chikungunya virus 
and dengue virus in Delhi, India. Emerging Infect Dis., 
15,1077–1080. https://doi.org/10.3201/eid1507.080638 
9. Chakravarti, A., Kumar, A. & Matlani, M. (2010). Displace-
ment of dengue virus type 3 and type 2 by dengue virus 
type 1 in Delhi during 2008. Indian J Med Microbiol 
28:412. https://doi.org/10.4103/0255-0857.71806 
10. Dhanoa, A., Hassan, S. S., Ngim. C.F., Lau, C. F., 
Chan,T.S., Adnan, N. A. A., Eng, W. W. H., Gan, H. M. & 
Rajasekaram, G. (2016). Impact of dengue virus (DENV) 
co-infection on clinical manifestations, disease severity 
and laboratory parameters. BMC Infect Dis., 16,:. https://
doi.org/10.1186/s12879-016-1731-8 
11. Dinkar, A., Singh, J., Prakash, P., Das, A. & Nath, G. 
(2018). Hidden burden of chikungunya in North India; A 
prospective study in a tertiary care centre. J Infect Public 
Health, 11,586–591. https://doi.org/10.1016/j.jiph.2017.0 
9.008 
12. Edwards, T., Signor, L. D. C. C., Williams C., Donis, E., 
Cuevas, E. L. & Adams, E. R. (2016). Co-infections with 
Chikungunya and Dengue Viruses, Guatemala, 2015. 
Emerging Infect Dis., 22,2003–2005. https://doi.o 
rg/10.3201/eid2211.161017 
13. Furuya-Kanamori, L., Liang, S., Milinovich, G., 
Magalhaes, R. J. S., Clements, A.C.A., Hu, W., Brasil, P., 
Frentiu, F.D.,  Dunning, R. & Yakob, L. (2016). Co-
distribution & co-infection of chikungunya and dengue 
viruses. BMC Infect Dis., 16,84. https://doi.org/10.1186/
s12879-016-1417-2 
14. Gandhi, B. S., Kulkarni, K., Godbole, M. & Dole, S.S. 
(2015). Dengue and chikungunya co-infection associated 
with more severe clinical disease than mono-infection. 
International Journal of Healthcare and Biomedical Re-
search, 3:117–23 
15. Gubler, D.J. (1998). Dengue and Dengue Hemorrhagic 
Fever. Clin Microbiol Rev 11:480–496 
16. Hammon, W. M., Rundnick, A. & Sather, G. E. (1960). 
Viruses Associated with Epidemic Hemorrhagic Fevers of 
the Philippines and Thailand. Science 131:1102–1103. 
https://doi.org/10.1126/science.131.3407.1102 
17. Hasebe, F., Parquet, M. C., Pandey, B. D., Mathenge, E. 
G. M., Morita, K., Balasubramaniam, V., Saat, Z., Yusop, 
A., Sinniah, M., Natkunam, S. & Igarashi, A. (2002). Com-
bined detection and genotyping of Chikungunya virus by a 
specific reverse transcription-polymerase chain reaction. 
Journal of Medical Virology, 67, 370–374. https://
doi.org/10.1002/jmv.10085 
18. Hisamuddin, M., Tazeen, A., Abdullah, M., Islamuddin, M., 
Parveen, N., Islam, A., Faizan, M. I., Hamza, A., Naqvi, I. 
H., Verma, H. N., Malik, A., Ahmed, A. & Parveen, S. 
(2018). Co-circulation of Chikungunya and Dengue virus-
es in Dengue endemic region of New Delhi, India during 
2016. Epidemiol Infect., 146, 1642–1653. https://doi.org/1 
0.1017/S0950268818001590 
19. Kaur, M., Singh, K., Sidhu, S.K., Devi, P., Kaur, M., 
Soneja, S. & Singh, N. (2018). Coinfection of chikungunya 
and dengue viruses: A serological study from North West-
ern region of Punjab, India. J Lab Physicians, 10,443–
447. https://doi.org/10.4103/JLP.JLP_13_18 
20. Kumari, R., Kumar, K. & Chauhan, L. S. (2011). First den-
gue virus detection in Aedes albopictus from Delhi, India: 
its breeding ecology and role in dengue transmission. 
Trop. Med. Int. Health, 16, 949–954. https://doi.org/1 
0.1111/j.1365-3156.2011.02789.x 
21. Kumaria, R. (2010). Correlation of disease spectrum 
among four Dengue serotypes: a five years hospital based 
study from India. Braz J Infect Dis 14:141–146 
22. Lanciotti, R.S., Calisher, C. H., Gubler, D. J., Chang, G.J. 
& Vorndam, A. V. (1992). Rapid detection and typing of 
dengue viruses from clinical samples by using reverse 
transcriptase-polymerase chain reaction. J. Clin. Microbi-
ol., 30, 545–551 
23. Londhey, V., Agrawal, S., Vaidya, N., Kini, S., Shastri, J. 
S. & Sunil, S. (2016). Dengue and Chikungunya Virus Co-
infections: The Inside Story. J Assoc Physicians India 
64:36–40 
24. Medina, F., Medina, J. F., Colón, C., Vergne, E., Santiago, 
G,A., & Munoz-Jordan, J.L. (2012). Dengue Virus: Isola-
tion, Propagation, Quantification, and Storage. Current 
protocols in microbiology Chapter 15:Unit15D.2. https://
doi.org/10.1002/9780471729259.mc15d02s27 
25. Mukherjee, S,, Dutta, S, K., Sengupta, S., Tripathi, A. 
(2017). Evidence of dengue and chikungunya virus co-
infection and circulation of multiple dengue serotypes in a 
recent Indian outbreak. Eur. J. Clin. Microbiol. Infect. Dis., 36, 
2273–2279. https://doi.org/10.1007/s10096-017-3061-1 
26. Murhekar, M., Kanagasabai, K., Shete, V., Joshua, V., 
Ravi, M., Kirubakran, B. K., Ramachandran, R., Sabarina-
than. & Gupta, N. (2019). Epidemiology of chikungunya 
based on laboratory surveillance data—India, 2016–2018. 
Trans. R. Soc. Trop. Med. Hyg., 113,259–262. https://
doi.org/10.1093/trstmh/try141 
27. Nayak, K., Jain, V., Kaur, M., Khan, N., Gottimukkala, K., 
Aggarwal,C., Sagar, R., Gupta, S., Rai, R. R., Dixit, K., 
Islamuddin, M., Khan, W. H., Verma, A., Maheshwari, D., 
Chawla, Y. M., Reddy, E. S., Panda, H., Sharma, P., 
Bhatnagar, P., Singh, P., Raghavendhar B, S., Patel, A. 
K., Ratageri, V. H., Chandele, A., Ray, P. & Murali-
Krishna, K. (2020). Antibody response patterns in 
chikungunya febrile phase predicts protection versus pro-
gression to chronic arthritis. JCI Insight. https://
doi.org/10.1172/jci.insight.130509 
28. National Vector Borne Disease Control Programme. In: 
Dengue Cases and Deaths in the Country since 2015. 
https://nvbdcp.gov.in/index4.php?
lang=1&level=0&linkid=431&lid=3715. Accessed 29 Aug 
2020 
29. National Vector Borne Disease Control programme. In: 
Epidemiological Profile of Chikungunya Fever in the 
Country since 2015. https://nvbdcp.gov.in/index4.php?
lang=1&level=0&linkid=486&lid=3765. Accessed 29 Aug 
2020 
30. Palomares-Reyes, C., Silva-Caso, W., Del Valle,  L. J., 
Aguilar-Luis, M. A., Weilg, C., Martins-Luna, J., Vinas-
Ospino, A., Stimmler, L., Espinoza, N. M., Ortega, R.A., 
Espiritu, W. E., Misaico, E. & De Valle-Mendoza, J.  
(2019). Dengue diagnosis in an endemic area of Peru: 
Clinical characteristics and positive frequencies by RT-
PCR and serology for NS1, IgM, and IgG. Int. J. Infect 
Dis., 81,31–37. https://doi.org/10.1016/j.ijid.2019.01.022 
31. Parveen, N., Islam, A., Tazeen, A., Hisamuddin, M., Ab-
dullah, M., Naqvi, I. H., Faizan, M. I., Gulyani, D., Ahmed, 
A. & Parveen, S. (2019). Circulation of single serotype of 
 
442 
Sagar, R. et al. / J. Appl. & Nat. Sci. 13(2), 433 - 442 (2021) 
Dengue Virus (DENV-3) in New Delhi, India during 2016: 
A change in the epidemiological trend. J. Infect Public 
Health, 12, 49–56. https://doi.org/10.1016/j.jiph.2018.0 
8.008 
32. Patil, H. P., Rane, P. S., Gosavi, M., Mishra, A. C. & 
Arankalle, V. A. (2020). Standardization of ELISA for anti-
chikungunya-IgG antibodies and age-stratified prevalence 
of anti-chikungunya-IgG antibodies in Pune, India. Eur. J. 
Clin. Microbiol. Infect Dis., https://doi.org/10.1007/s10096-
020-03933-5 
33. Phommanivong, V., Kanda, S., Shimono, T., Laaningao, 
P., Darcy, A.W., Mishima, N., Phaytanavanh, B & Nishiya-
ma, T. (2016). Co-circulation of the dengue with chikungu-
nya virus during the 2013 outbreak in the southern part of 
Lao PDR. Tropical Medicine and Health, 44, 24. https://
doi.org/10.1186/s41182-016-0020-y 
34. Ray, P., Ratagiri, V. H., Kabra, S. K., Lodha, R., Sharma, 
S., Sharma, B. S., Kalaivani, M., Wig, N. (2012). 
Chikungunya infection in India: results of a prospective 
hospital based multi-centric study. PLoS ONE, 7,e30025. 
https://doi.org/10.1371/journal.pone.0030025 
35. Requena-Castro, R., Reyes-López, M. Á., Rodríguez-
Reyna, R. E., Pailma-Nicolas, P. & Bocanegra-Garcia, V. 
(2017). Molecular detection of mixed infections with multi-
ple dengue virus serotypes in suspected dengue samples 
in Tamaulipas, Mexico. Mem Inst Oswaldo Cruz., 112,520
–522. https://doi.org/10.1590/0074-02760160468 
36. Rezza, G., El-Sawaf, G., Faggioni, G., Vescio, F., Santis, 
R. D., Helaly, G., Pomponi, A., Metwally, D., Fantini, M., 
Qudi, H., Ciccozzi, M. & Lista, F. (2014). Co-circulation of 
Dengue and Chikungunya Viruses, Al Hudaydah, Yemen, 
2012. Emerg Infect Dis., 20,1351–1354. https://
doi.org/10.3201/eid2008.131615 
37. Rosso, F., Pacheco, R., Rodríguez, S. & Bautista, D. 
(2016). Co-infection by Chikungunya virus (CHIK-V) and 
dengue virus (DEN-V) during a recent outbreak in Cali, 
Colombia: Report of a fatal case. Rev Chilena Infectol., 
33,464–467.https://doi.org/10.4067/S0716-101820160 
00400013 
38. Savargaonkar, D., Sinha, S., Srivastava, B., Nagpal, B. 
N., Sinha, A., Shamim, A., Das, R., Pande, V., Anvikar, A. 
R. & Valecha, N. (2018). An epidemiological study of den-
gue and its coinfections in Delhi. International Journal of 
Infectious Diseases, 74, 41–46. https://doi.org/10.1016/
j.ijid.2018.06.020 
39. Simon, F., Parola, P., Grandadam, M., Babrina, F., Ma-
nuela, O., Philippe, B., Pierre, H., Philippe, K., Ali, A. A., 
Xavier, D.L., Remi, C., & Hugues, T. (2007). Chikungunya 
infection: an emerging rheumatism among travelers re-
turned from Indian Ocean islands. Report of 47 cases. 
Medicine (Baltimore) 86,123–137. https://doi.org/10.1097/
MD/0b013e31806010a5 
40. Singh, J., Dinkar, A., Singh, R. G., Siddiqui, M. S., Sinha, 
N. & Singh, S. K. (2018). Clinical profile of dengue fever 
and coinfection with chikungunya. Ci Ji Yi Xue Za Zhi 
30,158–164. https://doi.org/10.4103/tcmj.tcmj_138_17 
41. Singh, P., Mittal, V., Rizvi, M. M. A., Chhabra, M., Shar-
ma, P., Rawat, D. S., Bhattacharya, D., Chauhan, L. S.  & 
Rai, A. (2012). The first dominant co-circulation of both 
dengue and chikungunya viruses during the post-
monsoon period of 2010 in Delhi, India. Epidemiol. Infect, 
140,1337–1342.https://doi.org/10.1017/S0950268811 
001671 
42. Subudhi, B. B., Chattopadhyay, S., Mishra, P., & Kumar, 
A. (2018). Current Strategies for Inhibition of Chikungunya 
Infection. Viruses 10:. https://doi.or g/10.3390/v10050235 
43. Taraphdar, D., Sarkar, A., Mukhopadhyay, B. B. & Chat-
terjee, S. (2012). A Comparative Study of Clinical Fea-
tures between Monotypic and Dual Infection Cases with 
Chikungunya Virus and Dengue Virus in West Bengal, 
India. The American Journal of Tropical Medicine and 
Hygiene, 86,720–723. https://doi.org/10.4269/ajtmh.201 
2.1 1-0704 
44. Zaidi, M. B., Garcia-Cordero, J., Rivero-Gomez, R., Corzo
-Gomez, J., Almeida, M. E. G. Y., Bonilla-Moreno, R., 
Bustos-Arriaga, J., Villegas-Sepulveda, N., Flores-Romo, 
L & Cedillo-Barron, L. (2018). Competitive suppression of 
dengue virus replication occurs in chikungunya and den-
gue co-infected Mexican infants. Parasit Vectors 11:378. 
https://doi.org/10.1186/s13071-018-2942-1 
 
 
 
 
 
 
 
 
 
 
 
 
